Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 26:9:593109.
doi: 10.3389/fpubh.2021.593109. eCollection 2021.

A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19

Xiaohua Liao  1 , Xin Lv  2 , Cheng Song  3 , Mao Jiang  2 , Ronglin He  2 , Yuanyuan Han  2 , Mengyu Li  2 , Yan Zhang  1 , Yupeng Jiang  1 , Jie Meng  2   4
Affiliations

A Retrospective Cohort Study on the Clinical Course of Patients With Moderate-Type COVID-19

Xiaohua Liao et al. Front Public Health. .

Abstract

Background: A large number of people contracted moderate-type COVID-19 around the world. However, to our knowledge no studies have covered the clinical course of patients with moderate-type COVID-19. This study describes the clinical course of moderate-type patients with COVID-19 from Wuhan City and Yiyang City, and explores factors relevant to the length of hospitalization and symptoms relief. Methods: The study analyzed the clinical course of 107 moderate-type patients with COVID-19 from the outbreak area (Wuhan) and the imported area (Yiyang), and used automatic linear modeling and multivariate linear regression analysis to explore the factors relevant to the length of hospitalization and symptoms relief. Furthermore, we created a scoring system to value the length of hospitalization and symptoms relief. Results: Lymphopenia, elevated C-reactive protein, increased LDH, bilateral lung GGO (ground glass opacity), and lung consolidation were more likely to appear in ordinary inpatients with moderate-type COVID-19 from Wuhan (P < 0.05), compared to infected medical staff from Wuhan and ordinary inpatients with moderate-type COVID-19 from Yiyang. Meanwhile, the length of hospitalization and symptoms relief was longer in ordinary patients with moderate-type COVID-19 from Wuhan (P < 0.05). Onset of symptoms to admission, ESR, leucocytes count, and bilateral lung GGO were linearly related to the length of hospitalization (P < 0.05); onset of symptoms to admission, leucocytes count, bilateral lung GGO, and lung consolidation were linearly related to the length of symptoms relief (P < 0.05). By using the scoring system, we found that the time of hospitalization and symptoms relief lengthened as the scores increased. Conclusions: This study described the clinical course of patients with moderate-type COVID-19, and found that ordinary patients with moderate-type COVID-19 in outbreak areas were more serious and needed stronger treatment and longer treatment time. Onset of symptoms to admission, ESR, leucocytes count, and bilateral lung GGO can be effective predictors of the length of hospitalization. And onset of symptoms to admission, leucocytes count, bilateral lung GGO, and lung consolidation can be effective predictors of the amount of time until symptoms relief. Most importantly, we have created a scoring system, which could contribute to the diagnosis and treatment of COVID-19.

Keywords: COVID-19; SARS-CoV-2; clinical course; moderate type; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Histogram of the length of hospitalization (P = 0.035).
Figure 2
Figure 2
Histogram of the length of symptoms relief (P = 0.107).
Figure 3
Figure 3
Using automatic linear modeling to predict relevant factors of the length of hospitalization.
Figure 4
Figure 4
Using automatic linear modeling to predict relevant factors of the length of symptoms relief.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Li H, Liu L, Zhang DY, Xu JY, Dai HP, Tang N, et al. . SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. (2020) 395:1517–20. 10.1016/S0140-6736(20)30920-X - DOI - PMC - PubMed
    1. Chen NS, Zhou M, Dong X, Qu JM, Gong FY, Han Yang, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. 10.1016/S0140-6736(20)30211-7 - DOI - PMC - PubMed
    1. Ceribelli A, Motta F, De SM, Ansari AA, Ridgway WM, Gershwin ME, et al. . Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J. Autoimmun. (2020) 109:102442. 10.1016/j.jaut.2020.102442 - DOI - PMC - PubMed
    1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat. Med. (2020) 26:450–2. 10.1038/s41591-020-0820-9 - DOI - PMC - PubMed
    1. Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, et al. . Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature. (2020) 583:282–5. 10.1038/s41586-020-2169-0 - DOI - PubMed

Publication types